• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

    76.70 -1.23 (-1.57%)
    Streaming Delayed Price Updated: 1:25 PM EDT, Apr 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 585,962
    Open 78.00
    Bid (Size) 76.61 (100)
    Ask (Size) 76.81 (100)
    Prev. Close 77.93
    Today's Range 76.17 - 78.90
    52wk Range 31.77 - 84.94
    Shares Outstanding 160,500,999
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
    In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL... 
    Via MarketMinute
    Topics Economy
    News headline image
    BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗
    BridgeBio Pharma (BBIO) shows a strong technical uptrend with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders. 
    Via Chartmill

    Performance

    YTD
    -2.0%
    -2.0%
    1 Month
    +8.0%
    +8.0%
    3 Month
    -3.0%
    -3.0%
    6 Month
    +35.8%
    +35.8%
    1 Year
    +120.1%
    +120.1%

    More News

    Read More
    News headline image
    Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Inc (NASDAQ:BBIO) Posts Q4 Revenue Beat on Heart Drug Surge, Eyes Multiple 2026 NDA Submissions ↗
    Via Chartmill
    News headline image
    BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio (BBIO) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio to Participate in March Investor Conferences
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗
    Via Stocktwits
    News headline image
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? ↗
    Via Stocktwits
    News headline image
    BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
    Via MarketMinute
    Topics ETFs Government Initial Public Offering
    News headline image
    CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    News headline image
    BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
    Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
    What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
    BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
    The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
    What is the current price of BridgeBio Pharma, Inc. - Common Stock?
    The current price of BridgeBio Pharma, Inc. - Common Stock is 76.70
    When was BridgeBio Pharma, Inc. - Common Stock last traded?
    The last trade of BridgeBio Pharma, Inc. - Common Stock was at 04/15/26 01:25 PM ET
    What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
    The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 12.31B
    How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
    BridgeBio Pharma, Inc. - Common Stock has 12B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.